1. Home
  2. PB vs CYTK Comparison

PB vs CYTK Comparison

Compare PB & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prosperity Bancshares Inc.

PB

Prosperity Bancshares Inc.

HOLD

Current Price

$64.27

Market Cap

7.1B

Sector

Finance

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

N/A

Current Price

$60.06

Market Cap

7.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PB
CYTK
Founded
1983
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
7.6B
IPO Year
1998
2004

Fundamental Metrics

Financial Performance
Metric
PB
CYTK
Price
$64.27
$60.06
Analyst Decision
Buy
Strong Buy
Analyst Count
14
18
Target Price
$79.54
$87.56
AVG Volume (30 Days)
1.0M
1.7M
Earning Date
04-29-2026
05-25-2026
Dividend Yield
3.67%
N/A
EPS Growth
13.27
N/A
EPS
5.72
N/A
Revenue
N/A
$13,368,000.00
Revenue This Year
$41.06
$9.79
Revenue Next Year
$17.19
$302.66
P/E Ratio
$11.42
N/A
Revenue Growth
N/A
N/A
52 Week Low
$61.07
$29.31
52 Week High
$77.20
$70.98

Technical Indicators

Market Signals
Indicator
PB
CYTK
Relative Strength Index (RSI) 26.95 41.25
Support Level $61.07 $59.25
Resistance Level $67.56 $65.93
Average True Range (ATR) 1.61 2.80
MACD -0.73 -0.36
Stochastic Oscillator 1.38 14.38

Price Performance

Historical Comparison
PB
CYTK

About PB Prosperity Bancshares Inc.

Prosperity Bancshares Inc provides retail and commercial banking services to individuals and small to midsize businesses. It provides a wide array of financial products and services to businesses and consumers throughout Texas and Oklahoma. The group provides Personal, Business, Mortgage, and Banking Services.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: